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ABSTRACT
Context Matrix metalloproteinases (MMPs) are associated with diastolic dysfunction and heart failure in
acquired heart disease.
Objective To investigate the role of MMPs as novel biomarkers in clinically stable adults with congenital
heart disease.
Methods We measured serum MMP-2, -3, -9 and tissue inhibitor of matrix metalloproteinase-1 in 425
patients and analysed the association with cardiac function and exercise capacity.
Results MMP-2 was significantly associated with exercise capacity, ventilatory efficiency and left
ventricular deceleration time, independently of age, sex, body surface area and NT-proBNP.
Conclusion MMP-2 may provide new information in the clinical evaluation of adults with congenital
heart disease.
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Introduction
Since Jerome Gross and Charles Lapiere initially described the
enzyme collagenase while observing the metamorphosis of
the tadpole in 1962, much research has been performed on
what is nowadays known as matrix metalloproteinase-1
(Gross & Lapiere, 1962). Many other members of the family of
matrix metalloproteinases (MMPs) and their tissue inhibitors
(TIMPs), consisting of structurally and functionally related
extracellular proteolytic enzymes, have been described (Visse
& Nagase, 2003). Together, these enzymes are capable of
degrading all kinds of extracellular matrix protein compo-
nents (Bode et al., 1999; Stetler-Stevenson et al., 1993). A dis-
ruption of the balance between MMPs and TIMPs is observed
in a wide variety of pathological conditions, such as acute
and chronic cardiovascular diseases, cancer progression and
different types of arthritis (Baker et al., 2002; Bode et al.,
1999; Jones et al., 2008; Konttinen et al., 1999). More specific,
altered MMP-2, MMP-9 and TIMP-1 levels have been associ-
ated with left ventricular (LV) hypertrophy, chronic heart fail-
ure and diastolic dysfunction in hypertensive heart disease
and coronary artery disease (Ahmed et al., 2006; Chu et al.,
2013; Kang et al., 2008; Laviades et al., 1998; Martos et al.,
2007). In patients with thoracic aortic aneurysms, specific
MMP-2, -9 and TIMP-1 profiles have been described; however,
the majority of research in this field is based on histology
of the aortic wall rather than circulating blood biomarker
levels (Ikonomidis et al., 2013; Wang et al., 2016; Zhang
et al., 2014).
To date, little is known about circulating MMP profiles in
adults with congenital heart disease (CHD). As biventricular
fibrosis, hypertrophy and dysfunction are important causes of
morbidity and mortality, the evaluation of MMPs may well
prove to be important in this setting. Therefore, the goal of
this study was to evaluate MMP profiles in adult CHD and to
investigate its relation with exercise capacity and echocardio-
graphic findings, in order to explore the potential role of
MMPs as new biomarkers.
Methods
Study design
This is a cross-sectional, observational study. Patients who
routinely visited our adult congenital cardiology outpatient
clinic between May 2011 and April 2013 were approached
and prospectively enrolled. At the same day, patients under-
went physical examination by a cardiologist, 12-lead electro-
cardiography, echocardiography and venous blood sampling.
A minority of patients underwent exercise testing for routine
clinical follow-up during the same week as the other study
investigations. According to the study protocol, these exercise
testing results were collected if performed as routine clinical
care. The study protocol was approved by the institutional
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review board of the Erasmus MC and written informed con-
sent was obtained from all subjects.
The following congenital cardiac diagnoses were included:
repaired tetralogy of Fallot (including pulmonary atresia with
ventricular septal defect), congenital aortic stenosis, aortic
coarctation, transposition of the great arteries (TGA) corrected
by atrial switch operation (Mustard/Senning), TGA corrected
by arterial switch operation, congenitally corrected TGA and
functionally univentricular hearts palliated by Fontan proced-
ure. Exclusion criteria were: age<18 years, severe renal
impairment (creatinine>200 lmol/L), pregnancy and mild car-
diac lesions (isolated atrial or ventricular septal defect).
Data collection
Patients were anonymised using a central online coding sys-
tem. All data collection was performed using an electronic
CRF-based online system (# 2004-2012 OpenClinica, LLC and
collaborators, Waltham, MA; www.OpenClinica.com). This
included patient demographics, medical history, medication
use, symptoms and signs of heart failure (New York Heart
Association (NYHA) classification), results of physical examin-
ation, electrocardiography, echocardiography, exercise cap-
acity and laboratory results.
Echocardiography
Patients underwent two-dimensional transthoracic echocardi-
ography using a commercially available ultrasound system
iE33 (Philips Medical Systems, Best, The Netherlands) with a
1.5-MHz transducer. Cardiac dimensions and function were
measured in accordance with the most recent recommenda-
tions of the American Society of Echocardiography and the
European Association of Cardiovascular Imaging (Lang et al.,
2015). Left ventricular (LV) and right ventricular (RV) dimen-
sions were measured in end-diastolic phase from the para-
sternal long-axis and RV-focused apical four-chamber view,
respectively. LV ejection fraction was calculated using the
biplane method of disc summation (modified Simpson’s rule).
RV systolic function was quantified by tricuspid annular plane
systolic excursion (TAPSE) and RV fractional area change.
Additionally, LV and RV systolic function was qualitatively
graded as normal or abnormal. LV diastolic function was
measured using pulsed wave Doppler echocardiography of
the mitral valve inflow (E, A and deceleration time) and tissue
Doppler imaging of the medial mitral annulus velocity from
the apical four-chamber view (E’). Echocardiographic measure-
ments of patients with a systemic (sub-aortic) RV were
assessed similar to patients with a sub-pulmonary RV.
Exercise capacity
Exercise testing was performed on an electrically braked cycle
ergometer (ergoselect 200 P, ergoline GmbH, Bitz, Germany),
using a gradually increasing workload of 20 W/min. It was
aimed to complete the test within 8–12min. Minute ventila-
tion, oxygen uptake and carbon dioxide elimination were
measured using a computerised breath-by-breath analyser.
Maximum effort was defined as a peak respiratory exchange
ratio of>1.10. Peak workload, heart rate and oxygen uptake
were expressed as percentage of the predicted value, based
on age, gender, body height and weight. Ventilatory effi-
ciency was expressed as carbon dioxide equivalent (minute
ventilation relative to carbon dioxide elimination).
Biomarkers
Venous blood samples were obtained after 30min of rest.
Plasma N-terminal-pro-B-type natriuretic peptide (NT-proBNP)
was assessed by electrochemiluminescence immunoassays
(Roche Diagnostics, Basel, Switzerland) in our clinical chemis-
try laboratory, as part of routine patient care. Other blood
samples were coded, processed and stored at –80 C within
2 h, until further analysis. Serum MMP-2, MMP-3 and MMP-9
were measured by batch analysis using the ProcartaPlexTM
Multiplex Immunoassay, with sample dilution factor 50
(eBioscience, Vienna, Austria). Serum TIMP-1 was measured
using two-site enzyme-linked immunosorbent assays, with
sample dilution factor 100 (BMS2018CE, eBioscience, Vienna,
Austria). Lower limits of detection were<34 pg/mL,<0.83 pg/
mL and<39 ng/mL for MMP-2, MMP-9 and TIMP-1, respect-
ively. As all blood samples were coded, laboratory staff was
blinded for patient data.
Statistical analysis
The distribution of data was checked using histograms and
the Shapiro–Wilk test. Patient characteristics were presented
as mean6 standard deviation or median [interquartile 1–3
(IQ1–IQ3)], depending on the distribution of data. Skewed bio-
marker distributions were log transformed.
Univariable associations were evaluated using Pearson’s
correlation. MMP values below the limit of detection were ana-
lysed as the lowest detectable value. We performed a stratified
Table 1. Characteristics of study population (n¼ 425).
Variable
Mean6 SD,
median [IQ1–IQ3]
or n (%)
Surgical repair/
intervention,
n (%)
Age, years 33.3 [25.9–42.1]
Sex, male n (%) 244 (57)
Diagnosis, n (%)
Tetralogy of Fallot 167 (39) 167 (100)
Congenital aortic stenosis 112 (26) 80 (71)
Aortic coarctation 40 (10) 39 (98)
TGA corrected by atrial switch 60 (14) 60 (100)
TGA corrected by arterial switch 18 (4) 18 (100)
Congenitally corrected TGA 18 (4) 9 (50)
Univentricular heart (Fontan) 10 (3) 10 (100)
Age at surgical repair/intervention, years 3.9 [0.8–11.9]
Systolic blood pressure, mmHg 1256 16
Diastolic blood pressure, mmHg 796 11
Heart rate, beats/min 746 14
Saturation <90%, n (%) 9 (2)
Cardiac medication, n (%)
ACE-inhibitor 61 (14)
Angiotensin receptor blocker 21 (5)
Betablocker 58 (14)
Diuretics 44 (10)
NT-proBNP, pmol/L 16.6 [7.9–34.3]
NYHA functional class, II–III n (%) 40 (9)
TGA: transposition of the great arteries; ACE: angiotensin converting enzyme;
NT-proBNP: N-terminal brain natriuretic peptide; NYHA: New York Heart
Association.
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analysis in the three main diagnostic groups (left-sided heart
disease, right-sided heart disease and systemic RV).
Multivariable linear (for continuous outcomes) and logistic
(for dichotomous outcomes) regression analyses were only
performed for MMP-2, as all other biomarker values yielded
non-significant results in the univariable analysis.
Unstandardised b-coefficients were adjusted for the potential
confounders age, sex and body surface area (BSA). Based on
the results of the univariable analysis, b-coefficients were
additionally adjusted for other covariates. Data analysis was
performed using IBM SPSS Statistics for Windows, Version
21.0 (IBM Corp., Armonk, NY). p Values<0.05 were consid-
ered statistically significant.
Results
We prospectively included 425 patients (median age 33.3
years [IQ1–IQ3 25.9–42.1 years], 244 males, 57%).
Echocardiography and measurement of serum MMPs was per-
formed in all patients. Bicycle ergometry was performed in
126 patients, of whom 40 patients underwent measurement
of oxygen uptake and carbon dioxide elimination. Clinical
characteristics and medication use are detailed in Table 1.
MMP and TIMP profiles were not different when comparing
all patient subgroups based on the congenital cardiac diagno-
sis (Figure 1).
Univariable analysis
In Table 2, the correlations of 10log MMP-2, MMP-3, MMP-9
and TIMP-1 with patient characteristics, exercise testing
results and echocardiographic data are presented. MMP-2 and
MMP-9 were significantly related to BSA, diastolic blood pres-
sure and decreased saturation. MMP-2 significantly correlated
with peak workload % (r¼0.233, p¼ 0.009), peak oxygen
uptake (r¼0.411, p¼ 0.008) and carbon dioxide equivalent
(r¼ 0.396, p¼ 0.034), of which scatterplots are additionally
shown in Figure 2. Furthermore, MMP-2 significantly corre-
lated to NT-proBNP, NYHA functional class, aortic valve peak
velocity, LV and RV systolic dysfunction, E’ wave velocity
<8 cm/s, E/E’ ratio13 and LV deceleration time. MMP-9 was
only related to peak oxygen uptake (r¼0.350, p¼ 0.027).
MMP-3, MMP-9, TIMP-1 and MMP-9/TIMP-1 ratios (ratios are
not presented in Table 2) were not significantly associated
with any other parameters of functional outcome. As 46% of
MMP-2 values were <34 pg/mL (lower limit of detection), all
Table 2. Univariable associations (Pearson’s correlation, n¼ 425).
Variable 10log MMP-2 10log MMP-3 10log MMP-9 10log TIMP-1
Patient characteristics
Age, years 0.027 0.093 0.049 0.063
Sex, male 0.066 0.151** 0.086 0.011
Body Surface Area, m2 0.173** 0.073 0.137** 0.048
Diagnosis: systemic right ventricle 0.009 0.018 0.043 0.097*
Surgical repair 0.080 0.039 0.069 0.005
Systolic blood pressure, mmHg 0.083 0.067 0.022 0.077
Diastolic blood pressure, mmHg 0.100* 0.017 0.111* 0.051
Heart rate, beats/min 0.042 0.018 0.012 0.003
Saturation <90% 0.136** 0.073 0.104* 0.074
Use of ARB 0.006 0.054 0.110* 0.038
10log NT-proBNP 0.147** 0.035 0.081 0.004
NYHA functional class, II–III 0.102* 0.064 0.018 0.034
Exercise testing
Peak heart rate, % of target (n¼ 126) 0.205* 0.024 0.001 0.088
Peak workload, % of target (n¼ 126) 0.233** 0.032 0.080 0.047
Peak oxygen uptake, mL/min (n¼ 40) 0.411** 0.004 0.350* 0.038
Peak oxygen uptake, % of target (n¼ 40) 0.230 0.141 0.056 0.119
Carbon dioxide equivalent (n¼ 40) 0.396* 0.214 0.270 0.148
Echocardiography
LV end-diastolic dimension, mm 0.100 0.005 0.072 0.022
Aortic STJ end-diastolic diameter, mm 0.056 0.070 0.051 0.085
Aortic valve peak velocity, m/s 0.110* 0.001 0.045 0.040
Interventricular septum, mm (PLAX) 0.028 0.092 0.010 0.020
RV end-diastolic annulus, mm 0.069 0.071 0.003 0.022
RV end-diastolic area, cm2 0.061 0.065 0.009 0.087
RV end-systolic area, cm2 0.096 0.061 0.002 0.078
Systolic function
LV ejection fraction, % 0.065 0.027 0.050 0.057
LV systolic dysfunction, 0–1 0.102* 0.093 0.073 0.011
RV fractional area change, % 0.112 0.017 0.019 0.022
RV systolic dysfunction, 0–1 0.115* 0.047 0.039 0.018
TAPSE, mm 0.017 0.079 0.081 0.018
LV diastolic function
E/A ratio 0.012 0.044 0.049 0.019
E’ wave <8 cm/s 0.132* 0.050 0.014 0.002
E/E’ ratio 13 0.128* 0.103 0.051 0.033
Deceleration time, ms 0.137* 0.085 0.017 0.061
MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloproteinase; ARB: angiotensin receptor blocker; NT-proBNP: N-terminal
brain natriuretic peptide; NYHA: New York Heart Association; LV: left ventricular; STJ: sinotubular junction; PLAX: parasternal long-axis view;
RV: right ventricular; TAPSE: tricuspid annular plane systolic excursion.
*p< 0.05,
**p< 0.01.
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analyses were repeated with exclusion of these values. Non-
parametric tests were also performed (Spearman’s correl-
ation). These did not yield different conclusions.
Stratified analysis
The associations of echocardiographic measurements with
MMP-2 as presented in Table 2 were additionally analysed in
three main diagnostic subgroups: left-sided heart disease
(congenital aortic stenosis, aortic coarctation and TGA cor-
rected by arterial switch operation), right-sided heart disease
(repaired tetralogy of Fallot), and systemic RV (TGA corrected
by atrial switch operation and congenitally corrected TGA). In
patients with repaired tetralogy of Fallot, LV dysfunction
(r¼ 0.184, p¼ 0.018), RV dysfunction (r¼ 0.190, p¼ 0.014), E/E’
ratio13 (r¼ 0.165, p¼ 0.042) and LV deceleration time
(r¼0.178, p¼ 0.028) were significantly associated with
MMP-2. These associations were not present in the two other
diagnostic groups, and LV diastolic function was not meas-
ured in patients with a systemic RV.
Multivariable analysis
In Table 3, the results of the multivariable analysis are pre-
sented. B-coefficients represent the increase in patient charac-
teristic per 10-fold increase in MMP-2, adjusted for age, sex
and BSA. Based on the results of the univariable analysis, we
additionally adjusted for diastolic blood pressure, decreased
saturation and NT-proBNP (not shown in the table). After
adjustment for all variables, MMP-2 was significantly associ-
ated with peak workload (b¼10.96, p¼ 0.022), carbon diox-
ide equivalent (b¼6.86, p¼ 0.016) and LV deceleration time
Figure 2. Scatterplots demonstrating the correlation of MMP-2 with peak workload %, peak oxygen uptake and carbon dioxide equivalent.
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(b¼22.4ms, p¼ 0.012); however, not with RV dilatation and
RV/LV systolic function. MMP-2 was not significantly associ-
ated with aortic sinotubular junction end-diastolic diameter,
although a trend was observed (b¼ 1.89, p¼ 0.087).
Discussion
In our cohort of clinically stable adults with congenital heart
disease, MMP-2 was significantly associated with decreased
exercise capacity (n¼ 126, peak workload %), decreased venti-
latory efficiency (n¼ 40, carbon dioxide equivalent) and
decreased LV deceleration time (n¼ 425), independently of
NT-proBNP and other clinical variables. In addition, MMP-2
was related to LV and RV systolic dysfunction (adjusted for
age, sex and BSA) and several echocardiographic markers of
diastolic dysfunction in univariable analysis. MMP-3, MMP-9
and TIMP-1 were not consistently related with exercise cap-
acity or cardiac function. Nor did we observe specific MMP
profiles among the varying underlying congenital diagnoses.
Cardiac function
Although this is the first study that reports a modest associ-
ation of MMP-2 with systolic ventricular function, independ-
ently of age, sex and BSA, extracellular matrix remodelling
processes have been previously related to systolic ventricular
function in other patient groups. In patients with hyperten-
sion, serum TIMP-1 levels were independently related to LV
longitudinal strain and torsion (Kang et al., 2008). Moreover,
TIMP-1 was elevated in patients with congestive heart failure
(Ahmed et al., 2006).
Increased extracellular matrix remodelling within the myo-
cardium has been more frequently associated with diastolic
ventricular dysfunction. In our cohort, diastolic dysfunction (as
expressed by E’ wave velocity<8 cm/s, E/E’ ratio13 and LV
deceleration time) was related to MMP-2 in univariable ana-
lysis. Martos et al. (2007) showed that in hypertensive heart
disease, serum levels of MMP-2 were elevated in those
patients with diastolic heart failure, suggesting increased deg-
radation of myocardial collagen and other components of the
extracellular matrix. Subsequently, Gardin et al. (2009) showed
that echocardiographic markers of diastolic dysfunction are
independently related to peak oxygen uptake and ventilatory
efficiency. In line with these results, Chen et al. (2013)
recently reported that a serum biomarker of collagen type I
synthesis (carboxy-terminal propeptide of procollagen type I,
PICP) was related to higher RV late gadolinium enhancement
scores (indicating myocardial fibrosis) and lower peak oxygen
uptake in patients with repaired tetralogy of Fallot. Diastolic
function is often impaired in adults with CHD (Eindhoven
et al., 2013). Diastolic dysfunction is especially common in
patients with congenital aortic stenosis (Dusenbery et al.,
2014; Friedman et al., 2013). In addition, abnormal LV diastolic
indices are known to be prevalent in a substantial proportion
of patients with tetralogy of Fallot (Aboulhosn et al., 2013).
The most important association found in our study, directly
linking increased serum MMP-2 values with decreased exer-
cise capacity and ventilatory efficiency, may therefore be par-
tially explained by increased diastolic dysfunction.
Importantly, the patients in our study were all clinically sta-
ble, with 91% of patients in NYHA class I. This probably
explains some of the only modest or absent correlations. The
stratified analysis in three main diagnostic groups showed that
the associations of echocardiographic measurements with
MMP-2 as found in the entire study cohort probably largely ori-
ginate from the group of patients with repaired tetralogy of
Fallot. This is possibly explained by a wider variance in ven-
tricular systolic and diastolic function in this patient group.
Aortic stenosis and dilatation
In our study, serum MMP-2, -3, -9 and TIMP-1 levels were
similar in patients with aortic stenosis or coarctation com-
pared with all other congenital cardiac diagnoses. As we
know patients with aortic stenosis or coarctation often have
diastolic dysfunction, we had expected higher MMP-2 levels
in these patients (Eindhoven et al., 2013). Neither did we find
significant relations with aortic dimensions as measured by
echocardiography, although a trend was observed for MMP-2
(adjusted p value 0.087). Previous studies have reported
altered plasma MMP-2, -9 and TIMP-1 levels in patients with
aortic valve stenosis and ascending aorta dilatation, both in
bicuspid valves and in chronic thoracic aortic dissection
(Ikonomidis et al., 2013; Wang et al., 2016; Zhang et al., 2014).
It may therefore be worthwhile to evaluate MMPs in specific
patient subgroups with a high risk of aortic dilatation, in com-
bination with more detailed imaging modalities of the aorta,
such as CT or MRI.
Table 3. Unstandardised B-coefficients of 10log MMP-2 values; analysed using
linear (for continuous outcome) or logistic regression (for categorical outcome),
n¼ 425.
Adjusted for age, sex, BSA
b p Value
NYHA functional class, II–III 0.57 0.152
Exercise testing
Peak heart rate, % of target (n¼ 126) 5.08 0.046
Peak workload, % of target (n¼ 126) 11.86 0.007
Peak oxygen uptake, mL/min (n¼ 40) 238.7 0.175
Peak oxygen uptake, % of target (n¼ 40) 12.79 0.046
Carbon dioxide equivalent (n¼ 40) 3.69 0.117
Echocardiography
LV end-diastolic dimension, mm 0.78 0.362
Aortic STJ end-diastolic diameter, mm 1.80 0.098
Aortic valve peak velocity, m/s 0.26 0.074
Interventricular septum, mm (PLAX) 0.00 0.997
RV end-diastolic annulus, mm 2.24 0.051
RV end-diastolic area, cm2 3.40 0.025
RV end-systolic area, cm2 3.49 0.010
Systolic function
LV ejection fraction, % 1.64 0.410
LV systolic dysfunction, 0–1 1.00 0.040
RV fractional area change, % 3.99 0.036
RV systolic dysfunction, 0–1 0.67 0.027
TAPSE, mm 0.39 0.627
LV diastolic function
E/A ratio 0.03 0.735
E’ wave <8 cm/s 0.56 0.107
E/E’ ratio 13 0.51 0.129
Deceleration time, ms 22.33 0.009
MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloprotei-
nase; ARB: angiotensin receptor blocker; NT-proBNP: N-terminal brain natriuretic
peptide; NYHA: New York Heart Association; LV: left ventricular; STJ: sinotubular
junction; PLAX: parasternal long-axis view; RV: right ventricular; TAPSE: tricuspid
annular plane systolic excursion.
Values in bold indicate p< 0.05.
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MMPs as peripheral markers
As circulating blood biomarkers profiles can be affected by
processes throughout the entire body, altered MMP profiles
may not entirely reflect the actual histological changes in the
myocardium or aortic wall. The interaction between MMPs
and other biologically active substrates is highly complex. We
constructed a conceptual model of the MMP–TIMP interac-
tions with TGF-b, IL-1b, TNF-a and other substrates as
described by the available literature on this topic (Figure 3)
(Brown et al., 2007; Friedberg et al., 2013; Jones et al., 2008;
Stetler-Stevenson et al., 1993; Vaday et al., 2001). Due to
these complex interactions, it is likely that the underlying dis-
ease and patient comorbidities influence MMP levels. In this
study, MMP-9 and TIMP-1 were not found to be associated
with echocardiographic data, in contrast to previous reports
(Ahmed et al., 2006; Chu et al., 2013; Martos et al., 2007). This
might be explained by the difference in patient cohorts, the
selection of stable patients visiting the outpatient clinic and
the type of MMP analysis performed.
Clinical implications
Previous studies have shown that exercise capacity and venti-
latory response to exercise are important prognostic markers
in adult CHD (Diller et al., 2005; Dimopoulos et al., 2006). Our
data provide evidence for a modest association of MMP-2 with
several measures of functional outcome, independently of NT-
proBNP. Correlations were not strong, indicating that MMP-2
only partially explains the variance in echocardiographic find-
ings and exercise capacity. Nevertheless, these findings indi-
cate that MMP-2 provides new information, incremental to
clinical variables and NT-proBNP, even in a clinically stable
patient group. MMP-2 may therefore be useful as novel bio-
marker in adults with CHD. It would be worthwhile to further
evaluate the prognostic value of MMP-2 in longitudinal
studies.
Study limitations
Bicycle ergometry was performed in a subset of 126 patients.
Of these, in 40 patients oxygen uptake and carbon dioxide
elimination were recorded. The consistency and strength of
these data should therefore be further evaluated in multiple
studies from different centres and laboratories, in accordance
with previously formulated benchmarks for the assessment of
novel cardiovascular biomarkers by Morrow and de Lemos
(2007). To be clinically useful, the preanalytical and analytical
performance of the MMP assays need to be thoroughly inves-
tigated and robust reference values have to be assessed in
healthy controls.
Conclusion
Serum MMP-2 was significantly related to exercise capacity,
ventilatory efficiency and LV deceleration time in a diverse
cohort of stable adults with congenital heart disease, also
after adjustment for NT-proBNP and other clinical variables. In
contrast, MMP-3, MMP-9 and TIMP-1 were not consistently
related to exercise testing results or cardiac function.
Prospective longitudinal studies are warranted to determine
the clinical usefulness and prognostic value of MMP-2 as can-
didate biomarker.
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Figure 3. Conceptual model illustrating the highly complex interactions between MMPs, TIMP-1 and other biologically active substrates (dashed lines indicate enzyme
inhibition). ARBs, angiotensin receptor blockers; CTGF, connective tissue growth factor; EGF, epidermal growth factor; ET-1, endothelin-1; IL-1b, interleukin-1beta;
PDGF, platelet derived growth factor; TGF-b, transforming growth factor-beta; TNF-a, tumour necrosis factor-alpha; uPA, urokinase-type plasminogen activator.
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